RxDoctor Payments Data

Sima Hodavance, MD

Cardiovascular Disease · Allentown, PANPI 1982921375

Payments from drug & device makers

$54,306in general payments, 2019–2025

Across 108 payments — averaging $502.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$36K
  • Janssen Research & Development, LLC$9K
  • Abbott$5K
  • Lilly USA, LLC$4K
  • Abiomed$140
  • Boston Scientific$118
  • plus $272 from 9 others

What the payments were for

  • Speaking & faculty fees$38,01084%
  • Travel & lodging$1,8694%
  • Food & beverage$5,23812%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,306 in reported general payments places this provider in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$96,464
Medicare patients
610
Services billed
1,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan110$137,911
EliquisApixaban105$108,202
JardianceEmpagliflozin85$68,003
FarxigaDapagliflozin Propanediol52$36,779
XareltoRivaroxaban27$32,681
Metoprolol Succinate154$3,209
Rosuvastatin Calcium77$973
Atorvastatin Calcium80$811
Lisinopril72$648
Potassium Chloride26$592
Bumetanide12$544
Torsemide16$517
Spironolactone69$515
Losartan Potassium55$508
Furosemide60$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36$137,911110 claims
Boehringer IngelheimJardiance$35,908$68,00385 claims
AstraZenecaFarxiga$14$36,77952 claims
Johnson & JohnsonXarelto$28$32,68127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →